Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Elixinol Global — Investor Presentation (April 2021)
19 slides from Elixinol Wellness's investor presentation, Apr 27, 2021
Slide 1: Investor Presentation April 2021
For personal use only Investor Presentation – April 2021 ASX:EXL | OTCQB:ELLXF Investor Presentation April 2021 Kind of Amazing Kind of Amazing
Slide 2: Disclaimer
Investor Presentation – April 2021 Disclaimer For personal use only This presentation contains summary information about Elixinol Global Limited (Elixinol) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunctio
Slide 3: Our Vision and Mission
Investor Presentation – April 2021 Elixinol CBD Our Vision For personal use only Building a global, hemp derived, health and wellness consumer products business. elixinolSkin CBD Our Mission Making a positive contribution to people’s health, wellness and the planet through the power of hemp products
Slide 4: Rejuvenated Leadership
Investor Presentation – April 2021 Rejuvenated Leadership For personal use only To facilitate the turn-around, new leadership capabilities have been put in place at all levels. Specific focus given to augmenting strategic, commercial and governance disciplines. Chair - Helen Wiseman Global CEO and E
Slide 5: An expanding global footprint
Investor Presentation – April 2021 An expanding global footprint For personal use only Our global footprint gives us access to high growth markets and diversifies risk. Japan • Most established and leading brand in Japan • Licensing agreement with Elixinol Japan, supply of AMERICAS (56% of Group Rev
Slide 6: Global CBD market outlook & regulations
Investor Presentation – April 2021 Global CBD market outlook & regulations For personal use only The global CBD industry is still in its early stages of consumer adoption. Regulations are changing fast and in favour of CBD. Regulation differs across key markets The UN accepts WHO’s recognising the m
Slide 7: FY2020 financial summary
Investor Presentation – April 2021 FY2020 financial summary For personal use only Well funded, reduced cost base and refocused on building a profitable consumer goods business. Annualised cost base 45% Substantial operational and corporate cost reduction program completed in June 2020. Well funded*
Slide 8: Q1 FY2021 update
Investor Presentation – April 2021 Q1 FY2021 update For personal use only Well funded, reduced cost base and refocused on building a profitable consumer goods business. Revenue by Month Operating cash Cash gross margin A$, 31 March 2021 quarter end expenditure reduced improvement 11% Driving margin
Slide 9: Key highlights of Q1 FY2021
Investor Presentation – April 2021 Key highlights of Q1 FY2021 For personal use only The proposed CannaCare acquisition marked a material advance in our strategy to become a global consumer goods business. A strong funding position, improving margin profitability at a reduced cost base and the rekin
Slide 10: Proposed acquisition of CannaCare Health to create a leading Pan-European CBD business
For personal use only Investor Presentation – April 2021 ASX:EXL | OCTQB:ELLXF Proposed acquisition of CannaCare Health to create a leading Pan-European CBD business 15 March 2021 Kind of Amazing Kind of Amazing
Slide 11: CannaCare overview
Investor Presentation – April 2021 CannaCare overview For personal use only CannaCare presents an opportunity to take a significant share of Europe’s fastest growing CBD market. • Established 2018, • Extensive product • CANOBO #1 brand • CANOBO first • Capital light model • Investment in new • Stric
Slide 12: CannaCare distribution and routes-to-market
Investor Presentation – April 2021 CannaCare distribution and routes-to-market For personal use only CannaCare enjoys a dominant position in traditional retail with particularly strong penetration in the drugstore channel (~42% market share 1) and pharmacies. Pharmacy/Drugstores E-Commerce Home Shop
Slide 13: Key people
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Key people For personal use only FRANK OTTO OLIVER HAIST Strategy Partner & Shareholder Managing Director Serial founder in the media industry L’Oréal – Group Key Account Manager FMCG Founder and investor of many successful Philips – I
Slide 14: Transaction summary
Investor Presentation – April 2021 Transaction summary For personal use only Elixinol plans to acquire leading German-based CBD business, CannaCare, to accelerate its vision of becoming a global, hemp-derived health and wellness consumer products business. • CannaCare’s CANOBO brand is the leading c
Slide 15: Financial Implications
Investor Presentation – April 2021 Financial Implications For personal use only The following sets out some key effects to the Company as a result of the Proposed Transaction proceeding: 1 Elixinol Group financial statements for year ended 31 December 2020 (audited). Annual EBITDA excludes asset imp
Slide 16: Timetable
Investor Presentation – April 2021 Timetable For personal use only Event Date Despatch of Notice Of Meeting to shareholders Thursday, 15 April 2021 (including Independent Expert’s Report) Annual General Meeting Monday, 17 May 2021 Targeted transaction completion Monday, 5 July 2021 Issue of Upfront
Slide 17: Takeaways
Investor Presentation – April 2021 Takeaways For personal use only Trusted & Broad hemp- Well positioned established based portfolio in high growth brand including food, global CBD / with fresh skincare and hemp nutraceuticals supplements categories offering Expanding Strong balance Optimised global
Slide 18: Q&A
For personal use only Investor Presentation – April 2021 ASX:EXL | OCTQB:ELLXF Q&A https://www.elixinolglobal.com/site/investor/investor-centre-home Kind of Amazing Kind of Amazing
Slide 19: For more information
For personal use only Investor Presentation – April 2021 For more information Investor relations and media please contact: Ron Dufficy, Global CFO ron.dufficy@elixinolglobal.com Kind of Amazing 19